Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  FUJIFILM Holdings Corporation    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

share with twitter share with LinkedIn share with facebook
10/16/2020 | 12:03pm EDT
FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug  approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo

TOKYO (Reuters) - Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.

Shares of the company closed roughly 3% higher on the news.

The Nikkei newspaper last month cited https://asia.nikkei.com/Spotlight/Coronavirus/Japanese-approval-sought-for-Avigan-to-treat-COVID-19 ministry sources saying approval could be granted to the drug within a month of its application.

Japan has already approved Avigan, known generically as favipiravir, as an emergency flu medicine, which is the subject of at least 16 clinical trials around the world. But concerns remain, as the drug has been shown to cause birth defects in animal studies.

Japan's government has called on Fujifilm to triple national stockpiles of the drug. The company said in a statement it has been working with strategic partners to meet that goal and requests by other countries to supply the drug.

Fujifilm in July signed a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid to sell Avigan for COVID-19 globally, excluding in China, Japan and Russia. The drug has been approved to treat COVID-19 in India and Russia.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

(Reporting by Chris Gallagher and Sayantani Ghosh; Editing by Stephen Coates, Edwina Gibbs and Shinjini Ganguli)


Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED 0.35% 5069.35 End-of-day quote.76.19%
FUJIFILM HOLDINGS CORPORATION -1.43% 5323 End-of-day quote.1.78%
NIKKEI 225 -0.44% 23567.04 Real-time Quote.0.06%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.34% 77.333 Delayed Quote.25.55%
share with twitter share with LinkedIn share with facebook
All news about FUJIFILM HOLDINGS CORPORATION
10/19Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/16Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/15REFILE-UPDATE 3-Fujifilm seeks approval for Avigan as COVID-19 treatment in J..
RE
10/15FUJIFILM : applies for approval of Avigan as COVID-19 treatment in Japan
RE
10/08Eli Lilly in deal to supply COVID-19 drugs to low-income countries
RE
10/08Eli Lilly in deal to supply COVID-19 drugs to low-income countries
RE
09/30FUJIFILM : signs manufacturing contract with U.S. firm VLP for COVID-19 vaccine
RE
09/30FUJIFILM : signs manufacturing contract with U.S. firm VLP for COVID-19 vaccine
RE
09/29Hitachi plans to sell Hitachi Metals in a deal worth over $6 bln - sources
RE
09/29FUJIFILM HOLDINGS CORPORATION : Ex-dividend day for interim dividend
FA
More news
Financials
Sales 2021 2 202 B 20 855 M 20 855 M
Net income 2021 122 B 1 159 M 1 159 M
Net Debt 2021 191 B 1 811 M 1 811 M
P/E ratio 2021 17,4x
Yield 2021 1,78%
Capitalization 2 159 B 20 468 M 20 448 M
EV / Sales 2021 1,07x
EV / Sales 2022 1,00x
Nbr of Employees 73 906
Free-Float 73,8%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 5 988,00 JPY
Last Close Price 5 400,00 JPY
Spread / Highest target 25,9%
Spread / Average Target 10,9%
Spread / Lowest Target -7,04%
EPS Revisions
Managers
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kouichi Tamai Director & Vice President
Takatoshi Ishikawa Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION3.25%20 468
CANON INC.-45.22%16 223
RICOH COMPANY, LTD.-44.04%4 582
BROTHER INDUSTRIES, LTD.-30.12%3 910
TOSHIBA TEC CORPORATION-4.87%2 242
GLORY LTD.-32.08%1 289